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REGULAR ARTICLE
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Key Points

• Despite increased incidence of CV events,
relative risk of CV AEs
with carfilzomib is low
and manageable; risk
of fatal AEs is not
elevated.
• Carfilzomib-based regimens have a favorable
benefit-risk profile in
RRMM; monitoring/
management of CV risk
is recommended.

Carﬁlzomib is a selective proteasome inhibitor approved for the treatment of relapsed
and/or refractory multiple myeloma (RRMM). It has signiﬁcantly improved outcomes,
including overall survival (OS), and shown superiority vs standard treatment with
lenalidomide plus dexamethasone and bortezomib plus dexamethasone. The incidence rate
of cardiovascular (CV) events with carﬁlzomib treatment has varied across trials. This
analysis evaluated phase 1-3 trials with .2000 RRMM patients exposed to carﬁlzomib to
describe the incidence of CV adverse events (AEs). In addition, the individual CV safety data
of .1000 patients enrolled in the carﬁlzomib arm of phase 3 studies were compared with
the control arms to assess the beneﬁt-risk proﬁle of carﬁlzomib. Pooling data across
carﬁlzomib trials, the CV AEs (grade $3) noted included hypertension (5.9%), dyspnea (4.5%),
and cardiac failure (4.4%). Although patients receiving carﬁlzomib had a numeric increase in
the rates of any-grade and grade $3 cardiac failure, dyspnea, and hypertension, the frequency
of discontinuation or death due to these cardiac events was low and comparable between
the carﬁlzomib and control arms. Serial echocardiography in a blinded cardiac substudy
showed no objective evidence of cardiac dysfunction in the carﬁlzomib and control arms.
Moreover, carﬁlzomib had no signiﬁcant effect on cardiac repolarization. Our results, including
the OS beneﬁt, showed that the beneﬁt of carﬁlzomib treatment in terms of reducing
progression or death outweighed the risk for developing cardiac failure or hypertension in most
patients. Appropriate carﬁlzomib administration and risk factor management are
recommended for elderly patients and patients with underlying risk factors.

Introduction
Multiple myeloma (MM) patients are at higher risk for cardiovascular (CV) events due to host factors
(eg, age and concurrent CV risk factors),1,2 disease factors (eg, renal failure, chronic anemia, concurrent
AL amyloidosis, hyperviscosity, A-V shunting),3-6 or toxicity associated with anti-MM treatment.
A retrospective cohort study of .23 000 MM patients indicated that 72% of newly diagnosed
MM (NDMM) patients and 71% of relapsed and/or refractory MM (RRMM) patients developed cardiac
events; arrhythmias (NDMM, 24%; RRMM, 29%) and heart failure (NDMM, 15%; RRMM, 15%) were the
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2 most common.7 To better understand the reason for high cardiac
event rates, a study of 7895 NDMM patients revealed that they have
a significantly higher incidence of hypertension, ischemic heart
disease, diabetes mellitus, and hyperlipidemia compared with ageand gender-matched controls.8 Older age ($75 years) and CV
event history are strongly associated with subsequent cardiac
adverse events (AEs) in MM patients.
Carfilzomib is a second-generation proteasome inhibitor that
irreversibly binds to the proteasome. 9 In the head-to-head
ENDEAVOR study comparing carfilzomib plus dexamethasone
(Kd) with bortezomib plus dexamethasone (Vd), Kd improved the
complete response rate, doubled progression-free survival (PFS),
and reduced the risk for death by 21%.10,11 Carfilzomib-based
combinations have significantly improved PFS and overall survival
(OS) by ;9 and 8 months, respectively, compared with standard
treatments (lenalidomide plus dexamethasone [Rd] and Vd) in
RRMM patients. Moreover, at first relapse, Kd and carfilzomib,
lenalidomide, and dexamethasone (KRd) have improved PFS by 12
months compared with Rd and Vd.12 In pivotal phase 2 and 3
studies, there has been a reported increase in CV AEs.10,13-15 In the
phase 3 ASPIRE and ENDEAVOR studies, the grade $3 cardiac
failure incidence was 3.8% (KRd) vs 1.8% (Rd) and 4.8% (Kd) vs
1.8% (Vd).10,15 Post hoc analyses of ASPIRE and ENDEAVOR data
according to age showed increased cardiac failure risk in elderly
patients. For KRd, the incidence of grade $3 cardiac failure was
higher in patients aged .70 years vs ,70 years (8.7% vs 2.1%).16
For Kd, grade $3 cardiac failure occurred more frequently in patients
$75 years of age compared with patients 65 to 74 years of age
(10.4% vs 4.9%) or those ,65 years of age (10.4% vs 2.7%).17
Because carfilzomib is approved and commonly used for RRMM, a
clear understanding of its CV safety and benefit-risk profile is
important. Herein, we describe CV AE incidences in .2000
carfilzomib-treated patients across phase 1-3 clinical trials. Given
the complex interplay among host, disease, and treatment factors
leading to CV events, it is difficult to isolate the role of treatment
factors in prospective single-arm phase 1/2 studies and retrospective studies. We compare CV events in the carfilzomib and control
arms of the ASPIRE, ENDEAVOR, and FOCUS phase 3 trials, in
which randomized design facilitates control for confounding host
and disease factors. Furthermore, we conducted a benefit-risk
analysis comparing the cumulative incidence of cardiac failure with
the cumulative incidence of disease progression or death in carfilzomibtreated patients.

Methods
We evaluated 11 phase 1-3 carfilzomib clinical trials with a cumulative
enrollment of 2044 patients to describe the incidence of CV AEs. This
CV safety analysis was based on phase 1/1b trials (PX-171-001,18 PX171-002 [NCT00150462],19 PX-171-006 [NCT00603447],20 and PX171-008),21 phase 2 trials (PX-171-003-A0/A1 [NCT00511238],22,23
PX-171-004 [NCT00530816],24 PX-171-005 [NCT00721734],25
and 2011-002 [NCT01410500]), the pivotal phase 3 trials ASPIRE
(PX-171-009 [NCT01080391])15 and ENDEAVOR (2011-003
[NCT01568866])10 that led to the approval of Kd or KRd for RRMM,
and the phase 3 FOCUS trial (PX-171-011 [NCT01302392])26
(supplemental Figure 1). Eligibility criteria for phase 1 and 2 studies
were presented previously. Key eligibility criteria for FOCUS, ASPIRE,
and ENDEAVOR are presented in supplemental Table 1. A majority of
phase 1-2 trial patients and all phase 3 trial patients had RRMM. Each
1634
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study protocol was approved by institutional review boards of all
participating institutions. Investigators obtained written informed consent
from all patients.
For this extended cardiac safety profile analysis (CV AE incidence)
in the ASPIRE, ENDEAVOR, and FOCUS trials and the benefit-risk
analysis for CV events (cumulative incidence of CV AEs vs
cumulative incidence of progression or death) in the ASPIRE and
ENDEAVOR trials, RRMM patients who received KRd (n 5 392),
Kd (n 5 463), and carfilzomib (n 5 157) in the ASPIRE,
ENDEAVOR, and FOCUS trials, respectively, were designated
the “carfilzomib” group. Patients who received Rd (n 5 389),
Vd (n 5 456), and best supportive care (BSC; n 5 153) in the
ASPIRE, ENDEAVOR, and FOCUS trials, respectively, were
designated the “control” group.

Analysis of CV AEs
The cardiac AEs of interest included in this study were cardiac
failure, hypertension, dyspnea, and ischemic heart disease. These
AEs were further characterized as any grade and grade $3. AEs
leading to dose reduction, discontinuation, or death were reported.
AEs were coded using the Medical Dictionary for Regulatory
Activities (MedDRA; version 15.1) and graded using the National
Cancer Institute Common Terminology Criteria for Adverse Events
(version 4.03),27 as reported by principal investigators. Cardiac
failure and hypertension were grouped per standardized MedDRA
query, narrow scope; dyspnea was based on preferred term; and
ischemic heart disease was grouped per standardized MedDRA
query, broad scope. Dyspnea events were not specifically
adjudicated for cardiac or pulmonary causes. AEs were collected
from informed consent through 30 days following last study
treatment dose. Treatment-emergent AEs were events that began
on or after first day of treatment or were conditions present at
baseline but worsened in severity after treatment.
All patients who received $1 dose of study treatment were included
in the safety analysis. Patient-level data were used for the CV
analysis. Cardiac AEs were reported by the principal investigator. In
the ENDEAVOR trial, AEs were reviewed by an independent
committee of 3 cardiologists for cardiac event adjudication based
on information supplied by trial sites. All study drug–related cardiac
AEs were followed to resolution or stabilization.

ENDEAVOR cardiopulmonary substudy
A subset of the overall ENDEAVOR trial population was enrolled
in the substudy. The cardiopulmonary-evaluable subgroup was
defined as all randomized patients who enrolled in the substudy
before randomization who had evaluable baseline echocardiograms. All patients provided substudy participation consent.
The prespecified primary end point of significant change in left
ventricular ejection fraction (LVEF) within 24 weeks from baseline was defined as $10% absolute reduction in LVEF from
baseline for baseline LVEF # 55% or a decrease to ,45% from
baseline LVEF . 55%.
Echocardiograms were performed at baseline, every 12 weeks (predose on day 1 of Kd cycles 3, 6, 9, and so forth), and at the end of
treatment to evaluate LVEF, right ventricular (RV) function, and
pulmonary artery systolic pressure (PASP). Echocardiogram results
are from the January 2017 data cutoff for the ENDEAVOR trial.
Patients were followed for .3 years. Diastolic to systolic RV
10 JULY 2018 x VOLUME 2, NUMBER 13

Table 1. Treatment-emergent CV AEs in carfilzomib-treated patients

across RRMM trials (N 5 2044)
Any-grade AEs
Cardiac failure
Cardiac failure congestive

Grade ‡3 AEs

Serious-grade AEs

137 (6.7)

90 (4.4)

79 (3.9)

51 (2.5)

36 (1.8)

34 (1.7)

Cardiac failure

38 (1.9)

20 (1.0)

19 (0.9)

Pulmonary edema

31 (1.5)

19 (0.9)

17 (0.8)

Ejection fraction decreased

16 (0.8)

6 (0.3)

0

7 (0.3)

5 (0.2)

4 (0.2)

Cardiac failure acute
Acute pulmonary edema

6 (0.3)

6 (0.3)

5 (0.2)

RV failure

3 (0.1)

3 (0.1)

2 (,0.1)

Acute left ventricular failure

2 (,0.1)

1 (,0.1)

2 (,0.1)

Cardiopulmonary failure

2 (,0.1)

1 (,0.1)

1 (,0.1)

Hepatic congestion

2 (,0.1)

2 (,0.1)

0

Cardiac failure chronic

1 (,0.1)

1 (,0.1)

0

Cardiogenic shock

1 (,0.1)

1 (,0.1)

0

Hepatojugular reflux

1 (,0.1)

0

0

Hypertension

378 (18.5)

120 (5.9)

13 (0.6)

Dyspnea

653 (31.9)

92 (4.5)

48 (2.3)

75 (3.7)

40 (2.0)

36 (1.8)

Ischemic heart disease

Pooled analysis is from the phase 1 trials (PX-171-001, PX-171-002, PX-171-006,
PX-171-008), the phase 2 trials (PX-171-003-A0, PX-171-003-A1, PX-171-004, PX-171-005,
and 2011-002), and the phase 3 ASPIRE (PX-171-009), ENDEAVOR (2011-003), and
FOCUS trials (PX-171-011). All data are n (%). Cardiac failure and hypertension events are
listed as standardized MedDRA query, narrow scope, and ischemic heart disease event is
listed as standardized MedDRA query, broad scope.

fractional area change was used as an RV function measurement. A cardiologist at the central echocardiography vendor read
the echocardiograms in a blinded manner. The cardiac events
adjudication committee determined whether a cardiac failure or
pulmonary hypertension–type outcome occurred based on clinically
significant changes in echocardiograms over time.
The mean 6 standard deviation for LVEF, RV function, and PASP
were calculated at each time point. A mixed model for repeated
measures under the assumption of missing-at-random was used as the
primary analysis to compare absolute values of LVEF, RV function, and
PASP between treatment arms. Least squares mean differences
between treatment arms and P values at each time point were reported.
The description of exposure-adjusted AE rate and methods for
corrected QT interval (QTc) analysis and benefit-risk analysis are
presented in the supplemental Methods.

Results
Incidence of CV AEs in pooled analysis
In a pooled analysis of 2044 carfilzomib-exposed patients across
phase 1-3 clinical trials, the most commonly reported CV AEs were
cardiac failure, hypertension, and dyspnea, with any-grade incidences of 6.7%, 18.5%, and 31.9%, respectively, and grade $3
incidences of 4.4%, 5.9%, and 4.5%, respectively (Table 1).

Patient and study characteristics in phase 3 trials
To better understand carfilzomib’s CV safety and benefit-risk profile,
a more detailed comparative analysis was performed with 1012
10 JULY 2018 x VOLUME 2, NUMBER 13

carfilzomib-treated patients across the phase 3 ASPIRE, ENDEAVOR,
and FOCUS trials (KRd, n 5 392; Kd, n 5 463; carfilzomib, n 5 157).
In the control arms, 389, 456, and 153 patients received Rd, Vd,
and BSC, respectively. Baseline and disease characteristics
were generally balanced between treatment arms, although a
higher proportion had a history of cardiac failure in the KRd arm
(4.3%) vs the Rd arm (1.3%) and in the BSC arm (6.5%) vs the
carfilzomib arm (3.8%) (Table 2).
Treatment exposure was longer in the carfilzomib arm vs the control
arms of the phase 3 trials, with a median duration of 72, 39.9, and
16.3 weeks of KRd, Kd, and carfilzomib, respectively, and 56.7
weeks of lenalidomide in the Rd arm, 26.8 weeks of bortezomib in
the Vd arm, and 10.7 and 10.1 weeks of corticosteroid and
cyclophosphamide, respectively, in the BSC arm (Table 3).

CV treatment-emergent AEs, treatment
discontinuations, and deaths in phase 3 trials
The rates of any-grade and grade $3 CV AEs (cardiac failure,
hypertension, dyspnea, and ischemic heart disease) for the
phase 3 ASPIRE, ENDEAVOR, and FOCUS trials are summarized in Table 4. The exposure-adjusted cardiac failure incidence
rate, which specified the number of patients with a cardiac failure
event over exposure time, was similar between the KRd and Rd
arms in the ASPIRE trial (3.94 and 3.14, respectively) and was
higher for the Kd arm than for the Vd arm in the ENDEAVOR trial
(11.23 and 5.17, respectively) (Table 5). Exposure-adjusted risk
for hypertension was higher in the carfilzomib arm vs the control
arm in the ASPIRE and ENDEAVOR trials (Table 5). Cardiac
failure event outcomes in the phase 3 trials are summarized in
Table 6.
To better understand the significance of AEs, we compared
common CV AEs leading to treatment reduction. In the ASPIRE
and ENDEAVOR trials, these were dyspnea (KRd, 1.3%; Rd,
0.3%; Kd, 2.8%; Vd, 1.1%), cardiac failure (KRd, 1.0%; Rd,
0.8%; Kd, 1.5%; Vd, 0%), and hypertension (KRd, 0.8%; Rd,
0.8%; Kd, 3.2%; Vd, 0.7%) (Table 4). No dose reduction due to
CV AEs was reported in the carfilzomib or control arm of the
FOCUS trial. Cardiac failure resulted in treatment discontinuation in 2 KRd patients (0.5%) and 3 Rd patients (0.8%) in the
ASPIRE trial, 13 Kd patients (2.8%) and 4 Vd patients (0.9%) in
the ENDEAVOR trial, and 4 carfilzomib patients (2.5%) and 2
BSC patients (1.3%) in the FOCUS trial (Table 4). Overall, 2.6%,
3.5%, and 3.2% of patients in the carfilzomib arm of the ASPIRE,
ENDEAVOR, and FOCUS phase 3 studies, respectively,
experienced cardiac failure events that led to missed doses of
carfilzomib. Carfilzomib was reinstated in 70% (ASPIRE), 75%
(ENDEAVOR), and 80% (FOCUS) of patients following a missed
dose.
The incidence of death due to cardiac failure was similar across
the phase 3 trial treatments. Deaths due to cardiac failure AEs
occurred in 3 patients (0.8%) receiving KRd and 4 patients (1.0%)
receiving Rd, 2 patients (0.4%) receiving Kd or Vd, and 2 patients
(1.3%) receiving carfilzomib or BSC (Table 4). Ischemic heart
disease AEs leading to death occurred in 3 patients (0.8%) in the
KRd arm, 2 patients (0.5%) in the Rd arm, 3 patients (0.7%) in the
Vd arm, and no patient in the Kd arm. No deaths from hypertension
or dyspnea AEs were reported in the ASPIRE, ENDEAVOR, and
FOCUS trials.
CARFILZOMIB CARDIOVASCULAR SAFETY PROFILE
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Table 2. Patients’ baseline and disease characteristics
ASPIRE
Characteristic
n

Carfilzomib (KRd)
392

Age, median (range), y
Age $75 y, n (%)
Sex, male/female, %

ENDEAVOR
Control (Rd)
389

Carfilzomib (Kd)
463

FOCUS

Control (Vd)
456

Carfilzomib (carfilzomib)

Control (BSC)

157

153

64.0 (38-87)

65.0 (31-91)

65.0 (35-89)

65.0 (30-88)

63.0 (32-85)

66.0 (43-81)

43 (11.0)

50 (12.9)

77 (16.6)

65 (14.3)

25 (15.9)

23 (15.0)

53.8/46.2

58.6/41.4

51.8/48.2

48.9/51.1

52.2/47.8

60.1/39.9

Eastern Cooperative Oncology Group
performance status, n (%)
0

164 (41.8)

174 (44.7)

220 (47.5)

228 (50.0)

49 (31.2)

1

189 (48.2)

181 (46.5)

211 (45.6)

199 (43.6)

78 (49.7)

30 (19.6)
89 (58.2)

2

39 (9.9)

34 (8.7)

32 (6.9)

29 (6.4)

29 (18.5)

33 (21.6)

I

167 (42.6)

152 (39.1)

204 (44.1)

200 (43.9)

29 (18.5)

31 (20.3)

II-III

217 (55.4)

230 (59.1)

259 (55.9)

256 (56.1)

125 (79.6)

120 (78.4)

International Staging System, n (%)

Serum b2 microglobulin, median (range), mg/L

3.5 (1.3-13.0)

3.6 (1.5-31.7)

3.6 (1.4-24.2)

3.7 (1.2-31.6)

5.3 (2.0-35.7)

5.9 (1.8-49.6)

Creatinine clearance, n (%), mL/min
,30

0

1 (0.3)

28 (6.0)

28 (6.1)

16 (10.2)

13 (8.5)

30 to ,50

24 (6.1)

30 (7.7)

57 (12.3)

69 (15.1)

29 (18.5)

40 (26.1)

50 to ,80

170 (43.4)

150 (38.6)

186 (40.2)

174 (38.2)

64 (40.8)

58 (37.9)

$80

197 (50.3)

203 (52.2)

192 (41.5)

185 (40.6)

48 (30.6)

41 (26.8)

History of hypertension

194 (49.5)

178 (45.8)

233 (50.3)

221 (48.5)

60 (38.2)

75 (49.0)

History of cardiac failure

17 (4.3)

5 (1.3)

14 (3.0)

13 (2.9)

6 (3.8)

10 (6.5)

History of cardiac arrhythmias

44 (11.2)

38 (9.8)

27 (5.8)

33 (7.2)

18 (11.5)

17 (11.1)

Medical history, n (%)

Cardiac failure and hypertension events are listed as standardized MedDRA query, narrow scope and ischemic heart disease event is listed as standardized MedDRA query,
broad scope.

QTc analysis
Electrocardiographic data were analyzed to determine the impact of
carfilzomib on cardiac function in patients with advanced malignancies, including MM. Carfilzomib plasma concentration had no
effect on QT interval with Fridericia’s correction (QTcF interval)
(supplemental Figure 2). The upper bounds of 1-sided 95%
confidence intervals (CIs) for predicted effects on QTcF and QT
interval with Bazett’s correction at maximum concentration were 4.8
and 5.9 milliseconds, respectively.

ENDEAVOR cardiac substudy
Of 929 patients in the ENDEAVOR trial, 159 patients (80 Kd and
79 Vd) enrolled in the substudy. For the primary end point, only
1 patient (Vd) had a significant reduction in LVEF within the first
24 weeks. Overall, 6 patients (3 Kd and 3 Vd) had a significant
decrease in LVEF at any time during the study that was mostly
reversible. Serial echocardiograms performed at baseline, every 3
months (for ;45 months), and at the end of the study indicated that
change in LVEF from baseline values for each visit was similar
across groups throughout the study (Figure 1). The mixed model for
repeated measures indicated no significant treatment or treatmentby-time interactions and no significant difference between the Kd
and Vd arms for LVEF and RV function at any time point (Table 7).
1636
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Benefit-risk analysis: time to first event of
cardiac failure and PFS or OS in the ASPIRE
and ENDEAVOR trials
In the ASPIRE trial, the cumulative grade $3 cardiac failure
incidence was slightly higher for KRd than for Rd. At 18 months
from randomization, the cumulative grade $3 cardiac failure
incidence was 4% for KRd and 2% for Rd (Figure 2A-B). The
cumulative incidence of MM disease progression or death at 18
months was 35% (KRd) vs 52% (Rd) (Figure 2A), and the
cumulative incidence of death due to any cause was 18% (KRd) vs
25% (Rd) (Figure 2B). The cumulative incidence of grade $3
cardiac failure for the ENDEAVOR trial was greater for Kd than for
Vd at 18 months from randomization (11% vs 5%) (Figure 2C-D).
The cumulative incidence of MM disease progression or death at 18
months was 48% (Kd) vs 78% (Vd) (Figure 2C), and the cumulative
incidence of death due to any cause was 20% (Kd) vs 29% (Vd)
(Figure 2D). The fact that the AE incidence was based on the
number of patients at risk and that the duration of therapy was
longer in the carfilzomib treatment arms (due to longer PFS) could
have contributed to the increased reported AEs. Exposure-adjusted
incidence rates for CV AEs are included in Table 5. Overall, the
difference in the cumulative incidence of progression was greater
than the difference in cumulative incidence of grade $3 cardiac
failure in the ASPIRE trial (eg, 17% vs 2% at month 18; Figure 2A)
10 JULY 2018 x VOLUME 2, NUMBER 13

3 200 mg (46.1-48 400.0)
204 mg (9.0-2868.0)
661.0 mg/m2 (40.0-4711.0)

The number needed to harm and number needed to
treat in the ASPIRE and ENDEAVOR trials
The number needed to harm (NNH) for the development of cardiac
failure or hypertension and the number needed to treat (NNT) to
prevent progression or death are presented in Table 8. The NNH for
grade $3 cardiac failure over 1 year was 102.8 for KRd patients in
the ASPIRE trial and 30.8 for Kd patients in the ENDEAVOR trial.
The NNH to develop 1 grade $3 hypertension event was 75.1 for
ASPIRE patients and 12.9 for ENDEAVOR patients.
The NNT for PFS indicates that 8.2 patients needed to be treated
with KRd instead of Rd and 2.5 patients needed to be treated with
Kd instead of Vd to prevent 1 PFS event over 1 year.

Discussion

Median PFS (months) for ASPIRE (Kd, 26.3; Vd, 17.6), ENDEAVOR (Kd, 18.7; Vd, 9.4) and FOCUS (K, 3.7; BSC; 3.3).
*Values for average dose per administration are for the time period beyond cycle 1 in the ENDEAVOR trial.
†Values represent average dose per cycle (in milligrams) for corticosteroid and cyclophosphamide in the FOCUS trial.

7875 mg (25.0-23400.0)
2362 mg/m2 (20.0-2902.0)
Total dose received
during study,
median (range)

5825 mg (75.0-26375.0)

2898 mg/m2 (39.6-8288.0)

36.3 mg/m2 (1.2-190.9)

1 083 mg (36.2-2 567.0)
65.0 mg (6.6-200.0)
26.4 mg/m2 (20.0-26.9)
1.2 mg/m2 (0.7-1.7)
55.9 mg/m2 (19.5-59.9)
25.0 mg (6.6-25.0)
25.0 mg (6.3-25.1)
26.8 mg/m2 (15.3-26.9)
Average dose per
administration,
median (range)*†

10.1 (0.10-138.3)

145
153

10.7 (0.4-138.3)
16.3 (0.3-138.4)

157
456

26.8 (1.0-106.1)
39.9 (1.0-108.1)

463
392

56.7 (0.4-200.7)

391

85.0 (0.1-185.0)
72.0 (1.0-93.1)

392
n

Treatment duration,
median (range), wk

Cyclophosphamide

BSC

Corticosteroid
Carfilzomib
Vd (control)
Kd
Rd (control)
KRd
KRd

FOCUS
Carfilzomib
Bortezomib
ENDEAVOR

Carfilzomib
Lenalidomide

ASPIRE
Carfilzomib

Table 3. Exposure to study treatment in phase 3 trials

and in the ENDEAVOR trial (eg, 30% vs 6% at month 18;
Figure 2C). More importantly, the difference in cumulative incidence
of death was greater than that for grade $3 cardiac failure in both
trials (Figure 2B,D) showing the favorable benefit-risk profile in
RRMM.
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Carfilzomib-based regimens have produced clinically meaningful
responses and shown significant improvement in the depth and
duration of responses in RRMM patients.10,15 More recently,
OS data showed superiority of Kd vs Vd and KRd vs Rd, with
a nearly 8-month increase in median OS in patients treated
with carfilzomib.11,28 Carfilzomib-based regimens have been
generally well tolerated, but concerns for CV toxicity have been
raised.10,13-15,29 Here, we assessed carfilzomib-associated CV
AEs in phase 1-3 clinical trials. Across all RRMM phase 3 trials,
treatment with carfilzomib was associated with a numeric increase
in cardiac AE incidence. Specifically, the incidence of any-grade
and grade $3 cardiac failure, hypertension, and dyspnea was
higher in carfilzomib-treated patients vs control-treated patients in
the phase 3 trials. In the pooled phase 1-3 trials, rates of grade $3
and serious-grade cardiac failure (grouped terms) were 4.4% and
3.9%, respectively. Importantly, however, the duration of exposure
and safety follow-up was longer for the carfilzomib arms in the
phase 3 studies; when adjusted for these differences, the
differences in the AE incidence between the 2 arms were less
prominent. In the ASPIRE trial, exposure-adjusted risk estimates
for cardiac failure, dyspnea, and ischemic heart disease were
comparable, whereas exposure-adjusted hypertension rates
remained higher in the carfilzomib arms vs control arms. In the
ENDEAVOR trial, exposure-adjusted risk estimates for cardiac
failure, hypertension, and dyspnea were lower than the unadjusted
incidence of these AEs, but were still higher in the carfilzomib arms
vs control arms.
Although these are phase 3 studies, AE reporting was not
performed by cardiologists. Moreover, none of these studies were
double blinded or included placebo, which could introduce
reporting bias. Additionally, the carfilzomib schedule in the phase
3 studies added 3-6 more visits per month to receive infusions,
thereby contributing to possible ascertainment bias. Thus, we
compared rates of death or treatment discontinuation due to CV
events, which were low and comparable between carfilzomib and
control arms across all studies.
An independent meta-analysis of all published carfilzomib clinical
studies (2623 patients from 25 studies) estimated grade $3
CARFILZOMIB CARDIOVASCULAR SAFETY PROFILE
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Table 4. Treatment-emergent CV AEs, treatment reduction, discontinuation, and deaths in the ASPIRE, ENDEAVOR, and FOCUS phase 3 trials
ASPIRE
Carfilzomib
(Krd) (n 5 392)
Carfilzomib dose, mg/m2

ENDEAVOR

Control
(Rd) (n 5 389)

Carfilzomib
(Kd) (n 5 463)

20/27

FOCUS

Control
(Vd) (n 5 456)

Carfilzomib
(carfilzomib) (n 5 157)

20/56

Control
(BSC) (n 5 153)

20/27

Treatment-emergent cardiac AEs
of interest, any-grade
Cardiac failure

25 (6.4)

16 (4.1)

38 (8.2)

13 (2.9)

12 (7.6)

Hypertension

62 (15.8)

32 (8.2)

120 (25.9)

44 (9.6)

25 (15.9)

7 (4.6)
9 (5.9)

Dyspnea

89 (22.7)

70 (18.0)

143 (30.9)

78 (17.1)

25 (15.9)

19 (12.4)

Ischemic heart disease

23 (5.9)

18 (4.6)

13 (2.8)

9 (2.0)

3 (1.9)

0

Treatment-emergent cardiac AEs
of interest, grade ‡3
Cardiac failure

15 (3.8)

7 (1.8)

22 (4.8)

8 (1.8)

9 (5.7)

5 (3.3)

Hypertension

22 (5.6)

8 (2.1)

44 (9.5)

12 (2.6)

6 (3.8)

0

Dyspnea

12 (3.1)

8 (2.1)

26 (5.6)

10 (2.2)

3 (1.9)

0

Ischemic heart disease

13 (3.3)

8 (2.1)

8 (1.7)

7 (1.5)

1 (0.6)

0

Reason for treatment reduction
Cardiac failure

4 (1.0)

3 (0.8)

7 (1.5)

0

0

0

Hypertension

3 (0.8)

3 (0.8)

15 (3.2)

3 (0.7)

0

0

Dyspnea

5 (1.3)

1 (0.3)

13 (2.8)

5 (1.1)

0

0

Ischemic heart disease

1 (0.3)

2 (0.5)

3 (0.6)

0

0

0

Cardiac failure

2 (0.5)

3 (0.8)

13 (2.8)

4 (0.9)

4 (2.5)

2 (1.3)

Hypertension

1 (0.3)

1 (0.3)

2 (0.4)

0

0

1 (0.7)

0

1 (0.3)

5 (1.1)

6 (1.3)

0

2 (1.3)

5 (1.3)

2 (0.5)

5 (1.1)

3 (0.7)

0

0

Cardiac failure

3 (0.8)

4 (1.0)

2 (0.4)

2 (0.4)

2 (1.3)

2 (1.3)

Hypertension

0

0

0

0

0

0

Dyspnea

0

0

0

0

0

0

3 (0.8)

2 (0.5)

0

3 (0.7)

0

0

Reason for treatment discontinuation

Dyspnea
Ischemic heart disease
Cause of death

Ischemic heart disease

Cardiac failure and hypertension events are listed as standardized MedDRA query, narrow scope, and ischemic heart disease is listed as standardized MedDRA query, broad scope. All
data are n (%), unless indicated otherwise.

cardiac failure and hypertension incidences at 2.5% and 4.3%,
respectively.30 Higher cardiac event rates have been observed in
some retrospective single-center studies, with doxorubicin
exposure associated with increased risk.31,32 Real-world data
based on the MarketScan Claims database showed an ;3%
incidence of hospitalizations due to cardiac AEs during
carfilzomib treatment, validating the low rate of grade $3 CV
AEs reported across carfilzomib clinical trials in real-world
practice.33
Evaluation of the possible effects of carfilzomib on cardiac function
by concentration-QTc analysis in cancer patients, including MM,
revealed that carfilzomib had no clinically significant impact on
cardiac repolarization. A substudy within the ENDEAVOR trial was
conducted using echocardiography to further characterize cardiopulmonary carfilzomib-associated toxicities based on changes in LVEF,
RV function, and PASP from baseline. Importantly, the assessment of
echocardiographic results, unlike the AE reporting, was done in a
1638
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blinded manner. Despite the increased incidence of cardiac failure
and hypertension events in the Kd arm vs the Vd arm, the .3-year
follow-up for this study revealed no objective evidence of subclinical
or clinically relevant declines in cardiac function for carfilzomib vs
bortezomib in terms of reductions in LVEF, RV, and PASP function.
This suggests that the mechanism resulting in increased cardiac
failure events in the Kd arm is not due to a direct cardiomyopathic
effect, distinct from other forms of chemotherapy, such as
trastuzumab or doxorubicin. The aggregate impact of an increase
in blood pressure, along with hydration administered with Kd
therapy, could play a significant role in the observed increase in
cardiac failure AEs reported with carfilzomib. A careful pretreatment
cardiac history, judicious use of hydration, and careful management
of systemic hypertension are recommended as good clinical
practice.
Additional surveillance strategies are needed for cardiopulmonary
AE monitoring. Future studies would need to explore the merit of
10 JULY 2018 x VOLUME 2, NUMBER 13

Table 5. Exposure-adjusted incidence of treatment-emergent CV AEs in the ASPIRE and ENDEAVOR trials
ASPIRE

ENDEAVOR

KRd
Total person
time (100
subject years)*

Rd

Kd

Vd

Exposure adjusted
risk estimate
(95% CI)

Total person
time (100
subject years)*

Exposure adjusted
risk estimate
(95% CI)

Total person
time (100
subject years)*

Exposure adjusted
risk estimate
(95% CI)

Total person
time (100
subject years)*

Exposure adjusted
risk estimate
(95% CI)

Cardiac failure

6.3

3.94 (2.66-5.83)

5.1

3.14 (1.92-5.12)

3.4

11.23 (8.17-15.44)

2.5

5.17 (3.00-8.90)

Hypertension

5.7

10.62 (8.26-13.65)

5.0

6.05 (4.23-8.66)

2.9

41.97 (35.09-50.19)

2.3

19.04 (14.17-25.59)

Dyspnea

5.6

15.82 (12.84-19.50)

4.5

15.66 (12.39-19.79)

2.6

54.37 (46.15-64.05)

2.2

36.02 (28.85-44.97)

Ischemic heart
disease

6.3

3.63 (2.41-5.46)

5.1

3.53 (2.22-5.60)

3.4

3.79 (2.20-6.53)

2.5

3.59 (1.87-6.90)

Cardiac failure and hypertension events are listed as standardized MedDRA query, narrow scope, and ischemic heart disease is listed as standardized MedDRA query, broad scope.
Dyspnea is a high-level term.
*Total person time is the sum of the time to first treatment-emergent AE for all patients in each treatment group.

comprehensive cardiac assessment for heart failure and other CV
events to clearly define CV risk factors. Careful clinical volume
status assessment may be a useful measure to proactively manage
patients at risk for developing heart failure. Increasing evidence
suggests a possible effect of proteasome inhibition on vascular
endothelium,34-37 rather than cardiac myocytes. Therefore, vascular
impact biomarkers should be investigated.
Although results from the ASPIRE and ENDEAVOR trials suggest
that higher carfilzomib doses might be associated with higher
incidences of cardiac AEs, conclusions drawn from cross-trial
comparisons should be made cautiously. The association between
carfilzomib dose and cardiac AE incidence is inconclusive.38 In 1
single-center study (n 5 60), no association was found between
carfilzomib dose and the incidence of cardiac events.39 Currently, 2
randomized trials are exploring the relationship between carfilzomib
dose and safety in MM patients. The phase 2 SWOG1304 study
compares 27 mg/m2 and 56 mg/m2 carfilzomib twice weekly. The
phase 3 A.R.R.O.W. study compares 70 mg/m2 carfilzomib once
weekly with carfilzomib 27 mg/m2 twice weekly.
The current benefit-risk analysis indicated that the cumulative
incidence of grade $3 cardiac failure was slightly higher for
the carfilzomib arms vs the control arms in the ASPIRE and
ENDEAVOR trials. Importantly, the reduction in the incidence of
progression or death between the carfilzomib and control arms

was greater than the difference in the cumulative cardiac failure
incidence between the 2 arms. NNT analyses indicated that
a small number of patients needed to be treated with KRd or
Kd vs control to prevent 1 PFS event over 1 year (NNT for KRd vs
Rd, 8.2; NNT for Kd vs Vd, 2.5). With respect to cardiac failure
NNH, ;103 and 31 patients were treated with KRd and Kd,
respectively, for 1 more patient who developed cardiac failure vs
control over 1 year. In addition, nearly 75 and 13 patients were
treated with KRd and Kd, respectively, for 1 more patient who
developed hypertension vs control. The smaller NNT vs NNH
values represent a larger treatment benefit than risk for KRd and
Kd. Overall, the results of this benefit-risk analysis suggest that the
benefit of carfilzomib treatment in terms of reducing progression
or death may outweigh the potential for developing cardiac failure
and hypertension.
Although CV AEs occurred throughout the course of carfilzomib
administration in the ASPIRE and ENDEAVOR trials, the cumulative
incidence curves (Figure 2) suggest a higher incidence of grade $ 3
cardiac failure earlier in treatment. Additionally, there is no evidence
for a correlation between carfilzomib-associated cardiac AEs and
cumulative dose. An exposure-response analysis using data from 10
phase 1-3 carfilzomib studies, aimed at evaluating carfilzomib safety
at various doses (15 to 56 mg/m2) and infusion lengths (2-10
minutes or 30 minutes), showed no statistically significant relationship

Table 6. Outcome of cardiac failure events in the ASPIRE, ENDEAVOR, and FOCUS trials
ASPIRE

Patients with cardiac failure, n

ENDEAVOR

FOCUS

Carfilzomib (KRd)

Control (Rd)

Carfilzomib (Kd)

Control (Vd)

Carfilzomib (carfilzomib)

Control (BSC)

25

16

38

13

12

7

15 (60.0)

6 (37.5)

14 (36.8)

8 (61.5)

6 (50.0)

1 (14.3)

Any-grade (standardized MedDRA query,
narrow scope) cardiac failure outcome, n (%)
Resolved
Resolved with sequelae
Not resolved
Deaths

2 (8)

0

0

0

10 (40)

10 (62.5)

23 (60.5)

5 (38.5)

6 (50)

5 (71.4)

4 (25.0)

2 (5.3)

2 (15.4)

2 (16.7)

2 (28.6)

3 (12.0)
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Figure 1. Change in LVEF from baseline: results from the ENDEAVOR cardiopulmonary substudy.

between these exposure parameters and rates of any-grade cardiac
failure.38
Elderly patients and patients with preexisting cardiac conditions,
such as cardiac failure and hypertension, could have an increased
risk for developing CV events while receiving carfilzomib.40,41 A
single-institution study to identify potential biomarkers in MM
patients at high risk for cardiac AEs when treated with carfilzomib
indicated a trend toward differential baseline expression of 8
proteins (tumor necrosis factor–related apoptosis-inducing ligand,
myoglobin, matrix metalloproteinase-1, heparin-binding EGF-like
growth factor, CD40 ligand, platelet-derived growth factor, heat
shock protein 27, and epidermal growth factor).42 Multivariate
analysis did not reveal any association between these proteins and
cardiac AEs. Furthermore, a single-institution prospective observational study of patients receiving carfilzomib- or bortezomib-based
therapy to assess CV risk factors and outcomes showed that
elevated baseline levels of brain natriuretic peptide (.100 pg/mL)

were associated with a higher risk for cardiac AEs in patients
treated with a carfilzomib-based regimen (odds ratio, 35.1; 95% CI,
4.3–289.5; P , .001).43 These findings are only hypothesis generating,
because this was not a randomized clinical study.
The potential for cardiac failure and hypertension must be
considered in the context of significant potential for reducing MM
disease progression or death. Nevertheless, closely monitoring
patients with risk factors for cardiac AEs is warranted. For patients
at higher risk for cardiac failure events, referral to a cardiologist
with expertise in cardio-oncology for comanagement is prudent.
Although it is unclear whether aggressively managing cardiac AE
risk factors will result in a reduction in cardiac failure events, it is
possible that controlling risk factors reduces event occurrences.
Because hypertension generally increases the risk for congestive
heart failure and predates it in a majority of cases,44,45 monitoring
and aggressively controlling high blood pressure at the start
and during treatment with carfilzomib is critical. In addition, dyspnea

Table 7. LVEF, RV function, and PASP estimation by mixed-model for repeated measures: data from the ENDEAVOR cardiopulmonary
substudy
LVEF estimation
Mean estimate
(Kd), %

Visit

Mean estimate
(Vd), %

RV function estimation
P

Mean estimate
(Kd), %

Mean estimate
(Vd), %

PASP estimation
P

Mean estimate
(Kd), mm Hg

Mean estimate
(Vd), mm Hg

P

Baseline

63.3

64.2

—

42.8

43.4

—

26.4

23.2

—

Week 12

63.38

63.70

0.6106

41.91

42.92

0.1025

28.72

25.30

0.0288

Week 24

62.84

63.22

0.5279

42.08

42.92

0.0936

28.00

26.23

0.2154

Week 36

62.29

62.75

0.5223

42.24

42.93

0.1804

27.27

27.15

0.9409

Week 48

61.75

62.27

0.5554

42.41

42.94

0.4046

26.55

28.08

0.4645

Week 60

61.21

61.79

0.5925

42.57

42.94

0.6508

25.82

29.00

0.2349

Week 72

60.66

61.32

0.6239

42.74

42.95

0.8363

25.10

29.92

0.1464

Week 84

60.12

60.84

0.6487

42.90

42.96

0.9641

24.37

30.85

0.1058

Week 96

59.58

60.36

0.6683

43.07

42.96

0.9471

23.65

31.77

0.0840

Data are least squares mean estimates.
—, P values were not reported at baseline for LVEF, RV function, and PASP estimations.
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Figure 2. Time to first event of cardiac failure (CF) and survival analyses in the ASPIRE and ENDEAVOR trials. (A) Time to first event of grade $3 CF and
progression or death in the ASPIRE (A) and ENDEAVOR (C) trials. Time to first event of grade $3 CF and mortality in the ASPIRE (B) and ENDEAVOR (D) trials. The x-axis
shows months since first dose for grade $3 CF AEs and months since randomization for PFS or OS.

is a common cardiopulmonary AE in carfilzomib-treated patients
and is a frequent presenting symptom for patients with cardiac
failure.10,28,46,47 Dyspnea may indicate volume overload in these
patients. For patients who have dyspnea while on carfilzomib, a
clinically driven evaluation for dyspnea causes should be sought.
Of note, patients experiencing dyspnea should be monitored, and
dyspnea should be managed immediately. Carfilzomib should be
withheld until dyspnea symptoms have resolved or returned to
baseline. Finally, when administering higher doses of carfilzomib
(.27 mg/m2), it is important to use a longer infusion time of 30
10 JULY 2018 x VOLUME 2, NUMBER 13

minutes. This has been shown to be well tolerated by reducing the
incidence of infusion-related reactions.48,49
In conclusion, the current analysis of CV events across carfilzomib
clinical trials conducted to date indicates that, although cardiac AEs
are numerically higher among carfilzomib-treated patients, the relative
risk remains relatively low and rarely leads to dose reductions or
treatment discontinuation. Moreover, the consequences are generally
manageable, with no higher risk for fatal outcomes. The results suggest
that the benefit of carfilzomib treatment in reducing disease progression,
and even death, outweighs CV risks for most patients. Nonetheless,
CARFILZOMIB CARDIOVASCULAR SAFETY PROFILE

1641

Table 8. NNH and NNT in ASPIRE and ENDEAVOR trials
ASPIRE

ENDEAVOR

Grade $3 cardiac failure*

102.8

30.8

Grade $3 hypertension†

75.1

12.9

8.2

2.5

Unfavorable effects: NNH (subject year)

Favorable effect: NNT (subject year)
PFS
*Based on standardized MedDRA query, narrow scope.
†Based on preferred term.

careful monitoring and management of CV risk factors, including blood
pressure and volume status, are recommended for all myeloma patients
as good clinical practice.
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